Ultragenyx Pharmaceutical Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated August 28, 2020, reports on executive leadership changes at Ultragenyx Pharmaceutical Inc. The filing details the appointment of a new Chief Financial Officer and the amended transition plan for the departing CFO.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and employment terms.
Material Changes
- Appointment of New CFO: Mardi C. Dier was appointed Executive Vice President and Chief Financial Officer, effective November 2, 2020.
- Departure of Former CFO: Shalini Sharp will cease serving as CFO on November 2, 2020, but will remain an employee until May 2, 2021.
- Compensation Structure: Ms. Dier's package includes a $550,000 base salary, a 45% target bonus, a $100,000 sign-on bonus, and equity awards (40,000 stock options and 40,000 RSUs).
- Transition Agreement Amendment: Ms. Sharp's resignation date was moved from September 2, 2020, to November 2, 2020. Her unvested equity will continue to vest for four months post-separation.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of general business risks. The primary contingency noted is the acceleration of Ms. Dier's equity vesting in the event of a "Covered Transaction" followed by termination without Cause or Constructive Termination.
Investor Verification Checklist
- Verify the effective date of Mardi C. Dier's tenure as CFO (November 2, 2020).
- Confirm the terms of the amended transition agreement for Shalini Sharp, specifically the May 2, 2021 separation date.
- Review the specific vesting schedules for the 40,000 stock options and 40,000 RSUs granted to Ms. Dier.
- Check the full text of the Offer Letter (Exhibit 10.1) and Transition Agreement Amendment (Exhibit 10.2) for detailed definitions of "Cause" and "Constructive Termination."